Tuesday, August 19, 2025 8/19/2025

Role of FABP5 in COPD Exacerbations

Award Number: R01HL141264
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2019
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Role of FABP5 in COPD Exacerbations - PROJECT SUMMARY Inflammation underlies the pathogenesis of many chronic lung diseases. Thus, defining mechanisms by which pulmonary inflammation is regulated and resolved is of high clinical importance. Understanding those mechanisms is especially relevant to chronic obstructive pulmonary disease (COPD), a condition that typically develops following decades of cigarette smoking (CS) and in which repeated respiratory infections are linked to non-resolving inflammation and can cause disease flares (COPD exacerbations). Lung macrophages are critical for both initiation and resolution of inflammation, and the control of exacerbations. They can adopt different phenotypes (i.e., pro-inflammatory or pro-repair) that are characterized by an interplay of transcriptional and metabolic programming dictating macrophage function and ensuring tissue integrity. We previously demonstrated that fatty acid binding protein 5 (FABP5) mediates pro-repair macrophage function via interaction with the nuclear receptor Peroxisome Proliferator-Activated Receptor γ (PPARγ) and identified a novel single nucleotide polymorphism (SNP), rs202275, linked with a FABP5 enhancer region and COPD exacerbations. However, the critical role of the FABP5/PPARg axis and the genetic variation rs202275 (T) in macrophage phenotypic programming and whether they can be targeted for therapeutic purposes remains unknown. We propose 3 aims to interrogate the role of the FABP5/PPARg axis in macrophage pro-repair phenotype relying on 1) metabolism, 2) transcription, and 3) function of lung macrophages. This work will provide an in-depth clinically relevant understanding of the mechanisms by which decreased FABP5 leads to chronic lung inflammation in COPD exacerbations, identify a novel target to reverse chronic inflammation in COPD, and validate the repurposing of FDA approved PPARγ agonists used in type 2 diabetes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $591,985 )
2025	2025	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	002	6	7/1/2025	NON-COMPETING CONTINUATION	$591,985
2025	2024	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	001	5	4/3/2025	COMPETING CONTINUATION	$35,285
2025	2022	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	4	4/3/2025	NON-COMPETING CONTINUATION	-$35,285
														Subtotal = $591,985

Issue Date FY: 2024 ( Subtotal = $597,510 )
2024	2024	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	002	5	7/29/2024	COMPETING CONTINUATION	$597,510
2024	2022	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	4	4/30/2024	NON-COMPETING CONTINUATION	$0
2024	2022	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	001	4	7/18/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $597,510

Issue Date FY: 2022 ( Subtotal = $495,444 )
2022	2022	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	001	4	6/14/2022	NON-COMPETING CONTINUATION	$49,545
2022	2022	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	4	4/5/2022	NON-COMPETING CONTINUATION	$445,899
														Subtotal = $495,444

Issue Date FY: 2021 ( Subtotal = $494,460 )
2021	2021	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	3	4/23/2021	NON-COMPETING CONTINUATION	$494,460
														Subtotal = $494,460

Issue Date FY: 2020 ( Subtotal = $492,000 )
2020	2020	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	2	4/16/2020	NON-COMPETING CONTINUATION	$492,000
														Subtotal = $492,000

Issue Date FY: 2019 ( Subtotal = $491,500 )
2019	2019	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Cardiovascular Diseases Research	000	1	6/7/2019	NEW	$491,500
														Subtotal = $491,500

Grand Total All Awards = $3,162,899

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Role of FABP5 in COPD Exacerbations

Award Number: R01HL141264

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2019

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer